DOCSLIB.ORG

Core-Binding Factor: a Central Player in Hematopoiesis and Leukemia 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Core-Binding Factor: a Central Player in Hematopoiesis and Leukemia 1 [CANCERRESEARCH (SUPPL.) 59, 1789s-1793s, April 1, 1999] Core-Binding Factor: A Central Player in Hematopoiesis and Leukemia 1 Nancy A. Speck, z Terry Stacy, Qing Wang, Trista North, Ting-Lei Gu, Janelle Miller, Michael Binder, and Miguel Marin-Padilla Departments of Biochemistry [N. A. S., T. S., Q. W., T.N., T-L. G., J. M.] and Anatomy and Pathology [M. B., M. M-P.], Dartmouth Medical School, Hanover, New Hampshire 03755 Abstract The Involvement of CBFs in Human Disease Consistent chromosomal rearrangements are found in a large number CBFa2 and CBF/3 are members of a small family of transcription of hematopoietic tumors. In many cases, these rearrangements disrupt factors known as CBFs or polyomavirus enhancer binding protein 2 genes whose normal function is required for the proper development of (1). CBFs are heterodimeric transcription factors that contain one blood cells. Excellent examples are the chromosomal rearrangements subunit that binds DNA directly (CBFc0 and a second, non-DNA- t(8;21)(q22;q22), t(12;21)(p13;q22), and inv(16)(p13q22) that disrupt two binding CBF/3 subunit (Fig. 1; Refs. 2-4). Four genes encode sub- of the genes encoding a small family of heterodimeric transcription fac- units of CBF in humans: three encode CBFa subunits (CBFA1, tors, core-binding factors (CBFs). CBFs consist of a DNA-binding CBFa CBFA2, and CBFA3); and one gene encodes the common CBF/3 subunit and a non-DNA-binding CBF/3 subunit. The t(8;21), associated with de novo acute myeloid leukemias, disrupts the CBFA2 (AML1) gene, subunit, CBFB (2-7). which encodes a DNA-binding CBFa subunit. The t(12;21), the most CBFs play critical roles in both normal developmental processes common translocation in pediatric acute lymphocytic leukemias, also and disease. The CBFA1 gene, which encodes a DNA-binding disrupts CBFA2. The CBFB gene, which encodes the non-DNA-binding CBFa subunit, is required for bone development. Mice lacking subunit of the CBFs, is disrupted by the inv(16) in de novo acute myeloid both copies of the Cbfal gene are completely lacking in bone leukemias. All chromosomal rearrangements involving the CBFA2 and formation, due to a defect in osteoblast differentiation (8, 9). The CBFB genes create chimeric proteins, two of which have been unequivo- human homologue, CBFA1, is implicated in a human genetic cally demonstrated to function as transdominant negative inhibitors of disorder, cleidocranial dysplasia, an autosomal dominant trait char- CBF function. acterized by moderate skeletal malformations (10). The mutations Both the Cbfa2 and Cbfb genes are essential for normal hematopoiesis in cleidocranial dysplasia patients inactivate only one copy of the in mice, because homozygous disruption of either gene blocks definitive CBFA1 gene, indicating that the disorder is caused by haploinsuf- hematopoiesis. Recent data suggest that Cbfa2 and Cbfb are required for the emergence of definitive hematopoietic stem cells in the embryo from a ficiency of CBFA1. putative definitive hemangioblast precursor. The transdominant negative The Cbfa2 and Cbfb genes are required tor fetal liver hematopoiesis inhibitor of CBF created by the inv(16), when present from the beginning in mice and play major roles in the etiology of many human leuke- of embryogenesis, also blocks the emergence of definitive hematopoietic mias. The human homologue of Cbfa2 (CBFA2, more commonly cells in the embryo. On the other hand, chromosomal translocations known as AML1) is disrupted by the t(8;21)(q22;q22), t(12;21)(p13; involving the CBFA2 and CBFB genes in leukemias block hematopoiesis q22), and t(3;21)(q26;q22) in acute myeloid and lymphocytic leuke- at later steps. This may reflect a difference in the timing at which mias and in therapy-related leukemias and myelodysplasias (Fig. 1; translocations are acquired in the leukemias, which presumably is subse- Refs. 5 and 11-14). The CBFB gene, which encodes the non-DNA- quent to emergence of the definitive hematopoietic stem cell. The cumu- binding CBFI3 subunit, is disrupted in acute myeloid leukemias by lative data suggest that although the earliest requirement for Cbfa2 and inv(16)(p13;q22), t(16;16), and del(16)(q22) (15). Together, CBFA2 Cbfb is for emergence of definitive hematopoietic stem cells, both genes are also required at later stages in the differentiation of some hematopoietic and CBFB are disrupted in approximately a quarter of all de novo lineages. acute leukemias, making them the most frequently disrupted genes in acute human leukemias (16-20). Introduction The chromosomal translocations involving the CBFA2 and CBFB genes generate chimeric proteins that contain all or part of CBFoz2 Hematopoiesis is the process by which blood cell populations of all (AML1) or CBFI3 fused to a segment of a protein encoded on the lineages are continuously renewed through differentiation I?om a other chromosome involved in the translocation (Fig. 2). The t(8;21) common progenitor cell called the pluripotent HSC. 3 Many transcrip- fuses the NH2-terminus of CBFoz2, including its DNA-binding do- tion factors are required for blood cell development, and several, such main, to a protein called ETO (for eight twenty one), encoded on as Scl, Rbtn2, E2A, and the subjects of this review, CBFo~2 (AML1) chromosome 8. The t(3;21) fuses the NH2-terminus of CBFoz2 to one and CBFI3, also play key roles in the dysregulation of hematopoiesis of three different proteins encoded by genes closely linked on chro- manifested as leukemia. mosome 3: EAP, MDS1, or EVIl. The t(12;21) breaks the CBFA2 gene 5' to the first coding exon and fuses the NH2-terminus of a protein in the ets family called TEL to the full-length CBFoz2 protein. Received 2/5/99; accepted 2/8/99. All of these chimeric CBFol2 proteins contain the CBFoz2 (AML1) The costs of publication of this article were defrayed in part by the payment of page DNA-binding domain, and they are believed to deregulate the tran- charges. This article must therefore be hereby marked advertisement in accordance with scription of CBF target genes in a transdominant manner (21-27). 18 U.S.C. Section 1734 solely to indicate this fact. 1 Presented at the "General Motors Cancer Research Foundation Twentieth Annual The inv(16) that disrupts the CBFB gene results in a chimeric Scientific Conference: DevelopmentalBiology and Cancer," June 9-10, 1998, Bethesda, protein that contains most of the CBF~ protein fused to the COOH- MD. This work was supported by USPHS Grants CA58343 and CA75611. N. A. S. is a Leukemia Society of America Scholar. terminal c~-helical rod domain from a SMMHC (Fig. 2; Ref. 15). It is 2 To whom requests for reprints should be addressed. thought that the CBFI3-SMMHC protein blocks wild-type CBF func- 3 The abbreviations used are: HSC, hematopoietic stem cell; CBF, core-bindingfactor; SMMHC, smooth muscle myosin heavy chain; dpc, days post coitus; AGM, aorta/genital tion by assembling into multimers that sequester CBFc~ subunits into ridge/mesonephros. nonfunctional complexes (28-30). 1789s Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 1999 American Association for Cancer Research. CBF IN HEMATOPOIESIS AND LEUKEMIA GENES DISEASE MUTATIONS CBFB AML M4Eo inv(16)(p13;q22) Fig. 1. The CBF complex and its association with leukemias. CBF binds the sequence CBFA 1 CCD Haploinsufficiency PyGPyGGT. The CBF/3 subunit forms a 1:1 com- plex with CBF~ and increases the binding affinity of CBFc~ for DNA (2, 4). Three genes encode CBFA2 ~ML1) AML M2 t(8;21)(q22;q22) CBFc~ subunits, and one of these genes, the CBFA2 gene, along with the CBFB gene, are the most frequently disrupted genes in acute human leuke- t-MDS t mias. t-AML t(3;21 )(q26.2;q22) CML-BC PyGPyGGT A L L t(12;21 )(p13 ;q22) CBFA3 Cbfa2 andCbfb Are Required for the Emergence of Definitive and are primarily primitive nucleated erythrocytes and small numbers Hematopoietic Stem Cells of granulocytes and macrophages (31). This first, transient wave of "primitive" yolk sac hematopoiesis is followed shortly thereafter by Gene disruption experiments in mice demonstrated that both Cbfa2 the appearance of "definitive" hematopoietic progenitor cells, which and Cbfb are required for the differentiation of all hematopoietic cells derived from the HSCs. Before describing the hematopoietic defect in are capable of differentiating into all adult blood cell lineages. De- Cbfa2- and Cbfb-deficient mice in more detail, it is worthwhile to finitive hematopoietic cells emerge from several sites in the embryo: briefly review the early steps of hematopoiesis in the developing from the extraembryonic yolk sac; the omphalomesenteric and um- embryo. bilical arteries; the embryonic splanchnopleure; and from the AGM Pluripotent HSCs are the source of all blood cells in the adult. region (32-37). The first-long term repopulating HSCs, which are However, paradoxically, they are not the first blood cells to develop cells capable of reconstituting an intact hematopoietic system when in the embryo. The first blood cells, which arise from mesoderm, transplanted into a lethally irradiated adult mouse, appear at 10.0 dpc appear in the extraembryonic yolk sac of mouse embryos at -8 dpc in the AGM region (36, 37). After their emergence, definitive hema- t(8;21) A t(12;21) t(3;21) CBF~2 (AML1) AML1-ETO ~....{:!...~:.~.:::~.:~.::::~...:~.:::~...::~.~:::.~::~.::~:..:2:~.~:.7:~:.~:..~:::~:.~:...~.:~.::.~::::~.:~:....~:.:~.::....:~.::.~.::~.:::~:~::~.] t(8;21) AML1-EAP t(3;21) AML1 -MDS1 / // / t(3;21) AML1 -EVIl t(3;21) TEL-AML1 I ~ ] t(12;21) inv(16) B CBF~ CBF~-SMMHC inv(16) Fig. 2. CBFot2 (AMLI) and CBF/3 fusion proteins. A, chimeric proteins resulting from chromosomal translocations involving the CBFA2 (AMLI) gene. Black rectangle, the DNA-binding domain. Sequences derived from fusion partners are indicated by the stippled, dashed, and lined rectangles.
Load more

Recommended publications
  • Transcriptome Profiling of Pediatric Core Binding Factor AML
    RESEARCH ARTICLE Transcriptome Profiling of Pediatric Core Binding Factor AML Chih-Hao Hsu1, Cu Nguyen1, Chunhua Yan1, Rhonda E. Ries2, Qing-Rong Chen1, Ying Hu1, Fabiana Ostronoff2, Derek L. Stirewalt2, George Komatsoulis1, Shawn Levy3, Daoud Meerzaman1☯, Soheil Meshinchi2☯* 1 Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, 20850, United States of America, 2 Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America, 3 Hudson Alpha Institute for Biotechnology, Huntsville, AL, United States of America ☯ These authors contributed equally to this work. * [email protected] Abstract The t(8;21) and Inv(16) translocations disrupt the normal function of core binding factors alpha (CBFA) and beta (CBFB), respectively. These translocations represent two of the most com- OPEN ACCESS mon genomic abnormalities in acute myeloid leukemia (AML) patients, occurring in approxi- Citation: Hsu C-H, Nguyen C, Yan C, Ries RE, Chen mately 25% pediatric and 15% of adult with this malignancy. Both translocations are Q-R, Hu Y, et al. (2015) Transcriptome Profiling of associated with favorable clinical outcomes after intensive chemotherapy, and given the per- Pediatric Core Binding Factor AML. PLoS ONE 10(9): ceived mechanistic similarities, patients with these translocations are frequently referred to as e0138782. doi:10.1371/journal.pone.0138782 having CBF-AML. It remains uncertain as to whether, collectively, these translocations are Editor: Ken Mills, Queen's University Belfast, mechanistically the same or impact different pathways in subtle ways that have both biological UNITED KINGDOM and clinical significance. Therefore, we used transcriptome sequencing (RNA-seq) to investi- Received: June 15, 2015 gate the similarities and differences in genes and pathways between these subtypes of pediat- Accepted: September 3, 2015 ric AMLs.
    [Show full text]
  • Variant Transcript in a Patient with Therapy-Related Acute Myeloid Leukemia by Routine Leukemia Translocation Panel Screen: Implications for Diagnosis and Therapy
    Downloaded from molecularcasestudies.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press COLD SPRING HARBOR Molecular Case Studies | RESEARCH ARTICLE Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy Andrés E. Quesada,1 Rajyalakshmi Luthra,1 Elias Jabbour,2 Keyur P. Patel,1 Joseph D. Khoury,1 Zhenya Tang,1 Hector Alvarez,1 Saradhi Mallampati,1 Guillermo Garcia-Manero,2 Guillermo Montalban-Bravo,2 L. Jeffrey Medeiros,1 and Rashmi Kanagal-Shamanna1 1Department of Hematopathology, 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA Abstract A 52-yr-old woman presented with therapy-related acute myeloid leukemia. A bone marrow biopsy showed 21% blasts with a myeloid phenotype and no other notable features such as abnormal eosinophils. Routine nanofluidics-based reverse transcriptase po- lymerase chain reaction (PCR) leukemia translocation panel designed to screen for recurrent genetic abnormalities in acute leukemia detected an inversion 16 transcript variant E. This prompted rereview of karyotype and fluorescence in situ hybridization studies, which con- firmed inv(16), leading to appropriate prognostication and modification of treatment. This Corresponding author: case underscores the utility of a powerful molecular screening method for the routine detec- [email protected] tion of recurrent genetic abnormalities of acute myeloid leukemia. It was especially useful in this case because of the lack of characteristic morphologic findings seen in inversion 16 and the difficulty in its detection by conventional karyotype analysis.
    [Show full text]
  • Core Binding Factor Β Is Required for Group 2 Innate Lymphoid Cell Activation
    Cutting Edge: Core Binding Factor β Is Required for Group 2 Innate Lymphoid Cell Activation This information is current as Xiaofei Shen, Mingwei Liang, Xiangyu Chen, Muhammad of September 24, 2021. Asghar Pasha, Shanti S. D'Souza, Kelsi Hidde, Jennifer Howard, Dil Afroz Sultana, Ivan Ting Hin Fung, Longyun Ye, Jiexue Pan, Gang Liu, James R. Drake, Lisa A. Drake, Jinfang Zhu, Avinash Bhandoola and Qi Yang J Immunol 2019; 202:1669-1673; Prepublished online 6 Downloaded from February 2019; doi: 10.4049/jimmunol.1800852 http://www.jimmunol.org/content/202/6/1669 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2019/02/05/jimmunol.180085 Material 2.DCSupplemental References This article cites 20 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/202/6/1669.full#ref-list-1 Why The JI? Submit online. by guest on September 24, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved.
    [Show full text]
  • Mechanism of Leukemogenesis by the Inv(16) Chimeric Gene CBFB/PEBP2B-MHY11
    Oncogene (2004) 23, 4297–4307 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $30.00 www.nature.com/onc Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11 Katsuya Shigesada*,1, Bart van de Sluis2 and P Paul Liu*,2 1Department of Cell Biology, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan; 2Oncogenesis and Development Section, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA Inv(16)(p13q22) is associated with acute myeloid leukemia subsequent to which a certain mechanism(s) should act subtype M4Eo that is characterized by the presence of to bring Runx1 into a functionally incompetent state in myelomonocytic blasts and atypical eosinophils. This the end (repression).If one of these steps were lacking or chromosomal rearrangement results in the fusion of CBFB impaired, CBFb-SMMHC would fail to elicit any and MYH11 genes. CBFb normally interacts with RUNX1 substantial dominant-negative effect regardless of how to form a transcriptionally active nuclear complex. well the other step might work. The MYH11 gene encodes the smooth muscle myosin Until recently, however, most functional studies of heavy chain. The CBFb-SMMHC fusion protein is CBFb-SMMHC have centered around the mechanism capable of binding to RUNX1 and form dimers and of repression, paying relatively little attention to the first multimers through its myosin tail. Previous results from heterodimerization step.Nevertheless, evidence sugges- transgenic mouse models show that Cbfb-MYH11 is able tive of its enhanced ability for heterodimerization to inhibit dominantly Runx1 function in hematopoiesis, (hyper-heterodimerization) has come from our previous and is a key player in the pathogenesis of leukemia.
    [Show full text]
  • Supplemental Information For
    Supplemental Information for: Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Mary E. Ross, Rami Mahfouz, Mihaela Onciu, Hsi-Che Liu, Xiaodong Zhou, Guangchun Song, Sheila A. Shurtleff, Stanley Pounds, Cheng Cheng, Jing Ma, Raul C. Ribeiro, Jeffrey E. Rubnitz, Kevin Girtman, W. Kent Williams, Susana C. Raimondi, Der-Cherng Liang, Lee-Yung Shih, Ching-Hon Pui & James R. Downing Table of Contents Section I. Patient Datasets Table S1. Diagnostic AML characteristics Table S2. Cytogenetics Summary Table S3. Adult diagnostic AML characteristics Table S4. Additional T-ALL characteristics Section II. Methods Table S5. Summary of filtered probe sets Table S6. MLL-PTD primers Additional Statistical Methods Section III. Genetic Subtype Discriminating Genes Figure S1. Unsupervised Heirarchical clustering Figure S2. Heirarchical clustering with class discriminating genes Table S7. Top 100 probe sets selected by SAM for t(8;21)[AML1-ETO] Table S8. Top 100 probe sets selected by SAM for t(15;17) [PML-RARα] Table S9. Top 63 probe sets selected by SAM for inv(16) [CBFβ-MYH11] Table S10. Top 100 probe sets selected by SAM for MLL chimeric fusion genes Table S11. Top 100 probe sets selected by SAM for FAB-M7 Table S12. Top 100 probe sets selected by SAM for CBF leukemias (whole dataset) Section IV. MLL in combined ALL and AML dataset Table S13. Top 100 probe sets selected by SAM for MLL chimeric fusions irrespective of blast lineage (whole dataset) Table S14. Class discriminating genes for cases with an MLL chimeric fusion gene that show uniform high expression, irrespective of blast lineage Section V.
    [Show full text]
  • Steffensen Et Al. Supplement 2A
    Liver Wild-type Knockout 1 2 4 1 2 4 1 1 1 C C C C C C W W W K K K IMAGE:640919 expressed sequence AA960558 IMAGE:523974 RIKEN cDNA 1810004N01 gene IMAGE:1211217 eukaryotic translation initiation factor 4E binding protein 2 IMAGE:314741 beta-site APP cleaving enzyme IMAGE:1038420 silica-induced gene 41 IMAGE:1229655 soc-2 suppressor of clear homolog C. elegans IMAGE:1150065 Unknown IMAGE:1038486 RIKEN cDNA 2700038M07 gene IMAGE:524351 amyloid beta A4 precursor protein IMAGE:819912 thymus expressed acidic protein IMAGE:779426 RIKEN cDNA 5230400G24 gene IMAGE:945643 ESTs IMAGE:850544 Mpv17 transgene, kidney disease mutant IMAGE:537568 expressed sequence AA675315 IMAGE:1107584 yes-associated protein, 65 kDa IMAGE:961363 expressed sequence AU015422 IMAGE:775218 expressed sequence AI265322 IMAGE:792656 protein phosphatase 1B, magnesium dependent, beta isoform IMAGE:1038592 ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal [H.sapiens] IMAGE:1224917 huntingtin interacting protein 2 IMAGE:751186 ESTs IMAGE:865151 Trk-fused gene IMAGE:523016 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 IMAGE:765039 FBJ osteosarcoma oncogene B IMAGE:1003995 expressed sequence AI844632 IMAGE:903863 RIKEN cDNA 1300006L01 gene IMAGE:934094 ESTs IMAGE:988962 expressed sequence C77245 IMAGE:1023308 ESTs, Weakly similar to S71512 hypothetical protein T2 - mouse [M.musculus] IMAGE:865317 eukaryotic translation initiation factor 3 IMAGE:720445 ribosomal protein S6 IMAGE:1005417 expressed sequence AU024550
    [Show full text]
  • Temporal Proteomic Analysis of HIV Infection Reveals Remodelling of The
    1 1 Temporal proteomic analysis of HIV infection reveals 2 remodelling of the host phosphoproteome 3 by lentiviral Vif variants 4 5 Edward JD Greenwood 1,2,*, Nicholas J Matheson1,2,*, Kim Wals1, Dick JH van den Boomen1, 6 Robin Antrobus1, James C Williamson1, Paul J Lehner1,* 7 1. Cambridge Institute for Medical Research, Department of Medicine, University of 8 Cambridge, Cambridge, CB2 0XY, UK. 9 2. These authors contributed equally to this work. 10 *Correspondence: [email protected]; [email protected]; [email protected] 11 12 Abstract 13 Viruses manipulate host factors to enhance their replication and evade cellular restriction. 14 We used multiplex tandem mass tag (TMT)-based whole cell proteomics to perform a 15 comprehensive time course analysis of >6,500 viral and cellular proteins during HIV 16 infection. To enable specific functional predictions, we categorized cellular proteins regulated 17 by HIV according to their patterns of temporal expression. We focussed on proteins depleted 18 with similar kinetics to APOBEC3C, and found the viral accessory protein Vif to be 19 necessary and sufficient for CUL5-dependent proteasomal degradation of all members of the 20 B56 family of regulatory subunits of the key cellular phosphatase PP2A (PPP2R5A-E). 21 Quantitative phosphoproteomic analysis of HIV-infected cells confirmed Vif-dependent 22 hyperphosphorylation of >200 cellular proteins, particularly substrates of the aurora kinases. 23 The ability of Vif to target PPP2R5 subunits is found in primate and non-primate lentiviral 2 24 lineages, and remodeling of the cellular phosphoproteome is therefore a second ancient and 25 conserved Vif function.
    [Show full text]
  • RUNX1 Together with a Compendium of Hematopoietic Regulators, Chromatin Modifiers and Basal Transcr
    Leukemia (2014) 28, 770–778 OPEN & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE CBFB–MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia A Mandoli1, AA Singh1, PWTC Jansen2, ATJ Wierenga3,4, H Riahi1, G Franci5, K Prange1, S Saeed1, E Vellenga3, M Vermeulen2, HG Stunnenberg1 and JHA Martens1 Different mechanisms for CBFb–MYH11 function in acute myeloid leukemia with inv(16) have been proposed such as tethering of RUNX1 outside the nucleus, interference with transcription factor complex assembly and recruitment of histone deacetylases, all resulting in transcriptional repression of RUNX1 target genes. Here, through genome-wide CBFb–MYH11-binding site analysis and quantitative interaction proteomics, we found that CBFb–MYH11 localizes to RUNX1 occupied promoters, where it interacts with TAL1, FLI1 and TBP-associated factors (TAFs) in the context of the hematopoietic transcription factors ERG, GATA2 and PU.1/SPI1 and the coregulators EP300 and HDAC1. Transcriptional analysis revealed that upon fusion protein knockdown, a small subset of the CBFb–MYH11 target genes show increased expression, confirming a role in transcriptional repression. However, the majority of CBFb–MYH11 target genes, including genes implicated in hematopoietic stem cell self-renewal such as ID1, LMO1 and JAG1, are actively transcribed and repressed upon fusion protein knockdown. Together these results suggest an essential role for CBFb–MYH11 in regulating the expression of genes involved in maintaining a stem cell phenotype. Leukemia (2014) 28, 770–778; doi:10.1038/leu.2013.257 Keywords: CBFb–MYH11; RUNX1; histone acetylation; acute myeloid leukemia; inv(16) INTRODUCTION Heterozygous Cbfb-Myh11 knock-in mice are embryonic lethal, Core-binding transcription factors (CBFs) have roles in stem cell with definitive hematopoiesis blocked at the stem-cell level.
    [Show full text]
  • Smac Mimetic Induces Cell Death in a Large Proportion of Primary Acute Myeloid Leukemia Samples, Which Correlates with Defined Molecular Markers
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 31 Research Paper Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers Sonja C. Lueck1, Annika C. Russ1, Ursula Botzenhardt1, Richard F. Schlenk1, Kerry Zobel2, Kurt Deshayes2, Domagoj Vucic2, Hartmut Döhner1, Konstanze Döhner1, Simone Fulda3,4,5,*, Lars Bullinger1,* 1Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany 2Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA, USA 3Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Germany 4German Cancer Consortium (DKTK), Heidelberg, Germany 5German Cancer Research Center (DKFZ), Heidelberg, Germany *Shared senior authorship Correspondence to: Lars Bullinger, email: [email protected] Simone Fulda, email: [email protected] Keywords: smac mimetic, IAP proteins, apoptosis, acute myeloid leukemia (AML), gene expression profiling (GEP) Received: March 31, 2016 Accepted: June 13, 2016 Published: July 02, 2016 ABSTRACT Apoptosis is deregulated in most, if not all, cancers, including hematological malignancies. Smac mimetics that antagonize Inhibitor of Apoptosis (IAP) proteins have so far largely been investigated in acute myeloid leukemia (AML) cell lines; however, little is yet known on the therapeutic potential of Smac mimetics in primary AML samples. In this study, we therefore investigated the antileukemic activity of the Smac mimetic BV6 in diagnostic samples of 67 adult AML patients and correlated the response to clinical, cytogenetic and molecular markers and gene expression profiles. Treatment with cytarabine (ara-C) was used as a standard chemotherapeutic agent. Interestingly, about half (51%) of primary AML samples are sensitive to BV6 and 21% intermediate responsive, while 28% are resistant.
    [Show full text]
  • Acute Myeloid Leukemia with Inv(16)
    Lv et al. Molecular Cytogenetics (2020) 13:4 https://doi.org/10.1186/s13039-020-0474-9 CASE REPORT Open Access Acute myeloid leukemia with inv(16)(p13.1q22) and deletion of the 5’MYH11/3’CBFB gene fusion: a report of two cases and literature review Lili Lv1, Jingwei Yu2 and Zhongxia Qi2* Abstract Background: Abnormalities of chromosome 16 are found in about 5–8% of acute myeloid leukemia (AML). The AML with inv(16)(p13.1q22) or t (16;16)(p13.1;q22) is associated with a high rate of complete remission (CR) and favorable overall survival (OS) when treated with high-dose Cytarabine. At the inversion breakpoints, deletion of 3’CBFB has been reported, but most of them were studied by chromosome and fluorescence in situ hybridization (FISH) analyses. The genomic characteristics of such deletions remain largely undefined, hindering further understanding of the clinical significance of the deletions. Case presentation: We report here two AML cases with inv(16) and deletion of the 5’MYH11/3’CBFB gene fusion, which were characterized by chromosome, FISH, and single nucleotide polymorphism (SNP) microarray analyses. Both cases have achieved CR for more than three years. Conclusions: Deletion of 3’CBFB in AML with inv(16) is also accompanied with deletion of 5’MYH11 in all the cases studied by SNP microarray, suggesting that 3’CBFB and 5’MYH11 were most likely deleted together as a fusion product of inv(16) instead of occurring separately. In concert with the findings of other published studies of similar patients, our study suggests that deletion of 5’MYH11/3’CBFB in AML with inv(16) may not have negative impact on the prognosis of the disease.
    [Show full text]
  • Molecular Identification of Cbfb-MYH11 Fusion Transcripts in an AML M4eo Patient in the Absence of Inv16 Or Other Abnormality By
    Correspondence 1907 spermatogenesis continues from puberty up to old age, there is more Alaez, Miriam Va´zquez and Gabriela de la Rosa for their very opportunity for preconceptional mutant gene accumulation in men helpful discussions. We also thank Mtra Sylvia Garcı´a of the John than in women. Benzo[a]pyrene is a potent carcinogen in cigarette Langdon Down Institute and to Dra Susana Ramı´rez Robles, Lic Ma smoke, its reactive metabolite induces DNA adducts, which can de los Angeles Rojas Ramı´rez and Dr Pedro Gonza´lez Vivanco of cause mutations. These DNA adducts were found in spermatozoa of the Integral Care for Persons with Down’s Syndrome (CTDUCA) for a smoker and his embryo.6 The 8-hydroxy-20- deoxyguanosine (8- providing the DS children included in this study. OhdG), a biomarker for oxidative DNA damage associated with 1,2 1 decreases in indices of sperm quality such as sperm number and JM Mejı´a-Arangure´ The Medical Research Unit on Clinical A Fajardo-Gutie´rrez1 Epidemiology, Hosp. de Pediatrı´a, sperm motility, was also found to be increased in these cases, 1,2 damaging the offspring. The early age peak in ALL (2–5 years) and H Flores-Aguilar Centro Me´dico Nacional Siglo XXI, IMSS, MC Martı´nez-Garcı´a1 Mexico; below 1 year in AML, support the hypothesis of environmental 3 2The Deptartment of Immunogenetics, exposure during gestation and preconception as being involved in F Salamanca-Go´mez V Palma-Padilla3 Instituto de Diagno´stico y Referencia its development. It is unknown as to which events might precipitate 4 Epidemiolo´gicos, SS, Mexico; R Paredes-Aguilera 3 the chromosome breaks whose improper repair initiates or promotes R Berna´ldez-Rı´os5 The Unit of Medical Research on Genetics, childhood AL.
    [Show full text]
  • How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript
    biomedicines Review How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring Annalisa Talami 1, Francesca Bettelli 1, Valeria Pioli 1 , Davide Giusti 1, Andrea Gilioli 1 , Corrado Colasante 1, Laura Galassi 1, Rachele Giubbolini 1, Hillary Catellani 1, Francesca Donatelli 1, Rossana Maffei 1 , Silvia Martinelli 1, Patrizia Barozzi 1 , Leonardo Potenza 1, Roberto Marasca 1 , Tommaso Trenti 2, Enrico Tagliafico 3 , Patrizia Comoli 4, Mario Luppi 1,*,†,‡ and Fabio Forghieri 1,*,† 1 Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy; [email protected] (A.T.); [email protected] (F.B.); [email protected] (V.P.); [email protected] (D.G.); [email protected] (A.G.); [email protected] (C.C.); [email protected] (L.G.); [email protected] (R.G.); [email protected] (H.C.); [email protected] (F.D.); [email protected] (R.M.); [email protected] (S.M.); [email protected] (P.B.); [email protected] (L.P.); [email protected] (R.M.) 2 Department of Laboratory Medicine and Pathology, Unità Sanitaria Locale, 41126 Modena, Italy; [email protected] 3 Center for Genome Research, Department of Medical and Surgical Sciences, University of Modena and Reggio Citation: Talami, A.; Bettelli, F.; Pioli, Emilia, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy; enrico.tagliafi[email protected] 4 V.; Giusti, D.; Gilioli, A.; Colasante, C.; Pediatric Hematology/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Galassi, L.; Giubbolini, R.; Catellani, Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy; [email protected] * Correspondence: [email protected] (M.L.); [email protected] (F.F.); H.; Donatelli, F.; et al.
    [Show full text]